Outlook Therapeutics (Outlook Therapeutics) 3-Year EBITDA Growth Rate : 22.80% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Outlook Therapeutics 3-Year EBITDA Growth Rate?

Outlook Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was $0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 22.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 45.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Outlook Therapeutics was 63.20% per year. The lowest was -15.20% per year. And the median was 43.80% per year.

Competitive Comparison of Outlook Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Outlook Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Outlook Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's 3-Year EBITDA Growth Rate falls into.

Outlook Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Outlook Therapeutics (NAS:OTLKW) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Outlook Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics (Outlook Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (NAS:OTLKW) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

OTLK:USA 41ON:Germany 41ON:Germany

Address

485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.